Insights & news

Catherine Longeval earns high praise from Who’s Who Legal: Life Sciences 2020

  • 16/04/2020
  • News
Catherine Longeval, head of the Van Bael & Bellis litigation practice, has been named “Recommended lawyer” by Who's Who Legal: Life Sciences for Product Liability 2020 and Life Sciences - Regulatory 2020.
 
Catherine is specialised in litigation before the Belgian courts with a particular emphasis on life sciences law, distribution law and unfair market practices. As regards life sciences law, she advises clients on a wide range of issues regarding the legislation governing medicines, biotech products, medical devices, cosmetics, food supplements and related products.
 
WWL recognises Catherine as “a premier name in life sciences in Belgium who is sought after for her excellent product liability defence work” and highlights that “Catherine Longeval enjoys a strong international reputation for the first-rate regulatory counsel she delivers to clients in the biotech and medical devices industries”.
 
"WWL: Life Sciences provides a comprehensive analysis of the leading lawyers around the world currently handling inter alia product liability proceedings as well as regulatory matters for high-profile clients across the sector."
 
The 2020 edition of WWL: Life Sciences can be found here.

Key contacts

Related insights

Sign up for updates
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more
    • 29/05/2020
    • Articles

    European Commission Presents EU4Health Programme

    On 28 May 2020 the European Commission (the Commission) presented details of its new, stand-alone EU4Health Programme, a proposal to commit considerable EU resources to health during the 2021-2027 period (EU4Health). The budget which the Commission proposes to earmark for EU4Health, EUR 9.4 billion, reflects a more than 20-fold increase over the funds previously dedicated to this policy area (EUR 413 million). The Commission first made its plan public as part of the presentation of ‘Next Generation EU’, a EURO 750 billion recovery plan to be embedded in and added to the long term overall EU budget for the 2021-2027 period (see, Van Bael & Bellis Life Sciences News Alert, 28 May 2020).

    Read more
    • 28/05/2020
    • Articles

    Next Generation EU - European Commission Proposes Significant Funding and Expanded EU Health Programme

    The European Commission (the Commission) published on 27 May 2020 its proposal for a major recovery plan and put forward a new EUR 750 billion recovery instrument called ‘Next Generation EU’ that would be embedded in and added to the long term EU budget (itself worth some EUR 1,100 billion between 2021 and 2027). The money from Next Generation EU would be available to the Member States in the form of both grants (EUR 500 billion) and loans (EUR 250 billion). The focus of the recovery plan is the green and digital transition but the plan also has a substantial health component, at times intertwined with green and digital aspects.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *